JP2016540505A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016540505A5 JP2016540505A5 JP2016533143A JP2016533143A JP2016540505A5 JP 2016540505 A5 JP2016540505 A5 JP 2016540505A5 JP 2016533143 A JP2016533143 A JP 2016533143A JP 2016533143 A JP2016533143 A JP 2016533143A JP 2016540505 A5 JP2016540505 A5 JP 2016540505A5
- Authority
- JP
- Japan
- Prior art keywords
- adenovirus
- cancer
- replication competent
- competent oncolytic
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361907860P | 2013-11-22 | 2013-11-22 | |
| US61/907,860 | 2013-11-22 | ||
| PCT/US2014/066920 WO2015077624A1 (en) | 2013-11-22 | 2014-11-21 | Adenovirus expressing immune cell stimulatory receptor agonist(s) |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019238013A Division JP2020048582A (ja) | 2013-11-22 | 2019-12-27 | アデノウイルス発現免疫細胞刺激受容体アゴニスト |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016540505A JP2016540505A (ja) | 2016-12-28 |
| JP2016540505A5 true JP2016540505A5 (enExample) | 2017-12-28 |
Family
ID=53180213
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016533143A Withdrawn JP2016540505A (ja) | 2013-11-22 | 2014-11-21 | アデノウイルス発現免疫細胞刺激受容体アゴニスト |
| JP2019238013A Pending JP2020048582A (ja) | 2013-11-22 | 2019-12-27 | アデノウイルス発現免疫細胞刺激受容体アゴニスト |
| JP2021097883A Pending JP2021137029A (ja) | 2013-11-22 | 2021-06-11 | アデノウイルス発現免疫細胞刺激受容体アゴニスト |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019238013A Pending JP2020048582A (ja) | 2013-11-22 | 2019-12-27 | アデノウイルス発現免疫細胞刺激受容体アゴニスト |
| JP2021097883A Pending JP2021137029A (ja) | 2013-11-22 | 2021-06-11 | アデノウイルス発現免疫細胞刺激受容体アゴニスト |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US20160289645A1 (enExample) |
| EP (2) | EP3653714A1 (enExample) |
| JP (3) | JP2016540505A (enExample) |
| KR (1) | KR20160137946A (enExample) |
| CN (2) | CN106029889A (enExample) |
| AU (1) | AU2014352749A1 (enExample) |
| CA (1) | CA2931322A1 (enExample) |
| DK (1) | DK3071697T3 (enExample) |
| ES (1) | ES2765489T3 (enExample) |
| SG (1) | SG10201907841UA (enExample) |
| WO (1) | WO2015077624A1 (enExample) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120087868A1 (en) | 2010-10-08 | 2012-04-12 | Gabriele Todd | Nanoparticle-loaded cells |
| SG11201507393TA (en) | 2013-03-14 | 2015-10-29 | Salk Inst For Biological Studi | Oncolytic adenovirus compositions |
| GB201322851D0 (en) | 2013-12-23 | 2014-02-12 | Psioxus Therapeutics Ltd | Method |
| HUE035875T2 (hu) | 2013-10-25 | 2018-06-28 | Psioxus Therapeutics Ltd | Heterológ géneket tartalmazó onkolitikus adenovírusok |
| GB201406608D0 (en) | 2014-04-12 | 2014-05-28 | Psioxus Therapeutics Ltd | Virus |
| KR102608590B1 (ko) | 2014-09-24 | 2023-12-01 | 솔크 인스티튜트 포 바이올로지칼 스터디즈 | 종양 살상 바이러스 및 이의 사용방법 |
| SG11201705844SA (en) * | 2015-02-06 | 2017-08-30 | Heat Biologics Inc | Vector co-expressing vaccine and costimulatory molecules |
| HRP20200439T1 (hr) | 2015-04-30 | 2020-06-12 | Psioxus Therapeutics Limited | Onkolitički adenovirus koji kodira protein b7 |
| SG11201708804WA (en) | 2015-05-07 | 2017-11-29 | Agenus Inc | Anti-ox40 antibodies and methods of use thereof |
| ES2994611T3 (en) * | 2015-10-19 | 2025-01-27 | Cg Oncology Inc | Methods of treating solid or lymphatic tumors by combination therapy |
| CN108883173B (zh) | 2015-12-02 | 2022-09-06 | 阿吉纳斯公司 | 抗体和其使用方法 |
| BR112018012180A2 (pt) | 2015-12-17 | 2018-12-04 | Psioxus Therapeutics Ltd | vírus de codificação de um anticorpo ou fragmento de complexo anti-tcr |
| US10612005B2 (en) | 2016-01-08 | 2020-04-07 | Replimune Limited | Modified oncolytic virus |
| WO2017147269A1 (en) | 2016-02-23 | 2017-08-31 | Salk Institute For Biological Studies | Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics |
| WO2017147265A1 (en) | 2016-02-23 | 2017-08-31 | Salk Institute For Biological Studies | High throughput assay for measuring adenovirus replication kinetics |
| WO2017156349A1 (en) | 2016-03-10 | 2017-09-14 | Cold Genesys, Inc. | Methods of treating solid or lymphatic tumors by combination therapy |
| CN109789177A (zh) * | 2016-05-27 | 2019-05-21 | 德那翠丝有限公司 | 腺病毒和免疫调节剂组合治疗 |
| GB201713765D0 (en) | 2017-08-28 | 2017-10-11 | Psioxus Therapeutics Ltd | Modified adenovirus |
| IL303187A (en) | 2016-08-29 | 2023-07-01 | Akamis Bio Ltd | Adenovirus with bispecific T cell activator |
| ES2845690T3 (es) * | 2016-09-12 | 2021-07-27 | Targovax Oy | Combinación de adenovirus e inhibidores de punto de control para el tratamiento del cáncer |
| MA46770A (fr) | 2016-11-09 | 2019-09-18 | Agenus Inc | Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation |
| EP3532082A4 (en) | 2016-12-12 | 2020-08-26 | Salk Institute for Biological Studies | SYNTHETIC ADENOVIRUS TUMOR TARGETING AND THEIR USES |
| KR20190112263A (ko) * | 2016-12-12 | 2019-10-04 | 멀티비르 인코포레이티드 | 암 및 감염성 질환의 치료 및 예방을 위한 바이러스 유전자 치료요법 및 면역 체크포인트 억제제를 포함하는 방법 및 조성물 |
| KR20190098215A (ko) | 2016-12-21 | 2019-08-21 | 멤젠 엘엘씨 | 무장된 복제-가능 종양 분해 아데노바이러스 |
| US11298420B2 (en) * | 2016-12-21 | 2022-04-12 | Memgen, Llc | Armed oncolytic viruses |
| GB201700350D0 (en) | 2017-01-09 | 2017-02-22 | Replimune Ltd | Altered virus |
| CN108338994A (zh) | 2017-01-25 | 2018-07-31 | 杭州康万达医药科技有限公司 | 溶瘤病毒作为用于治疗肿瘤和/或癌症的免疫刺激剂的应用 |
| CA3058938A1 (en) | 2017-04-04 | 2018-10-11 | Heat Biologics, Inc. | Intratumoral vaccination |
| EP4599893A3 (en) | 2017-04-14 | 2025-11-05 | CG Oncology, Inc. | Cg0070 for treating bcg resistant bladder carcinoma in situ |
| CN109276580B (zh) * | 2017-07-21 | 2021-08-24 | 厦门大学 | 一种用于治疗肿瘤的病毒 |
| WO2019032628A1 (en) | 2017-08-07 | 2019-02-14 | The Regents Of The University Of California | GENERATING PLATFORM FOR SAFE CELLULAR THERAPEUTIC AGENTS |
| SG11202004680UA (en) | 2017-11-22 | 2020-06-29 | Mesoblast Int Sarl | Cellular compositions and methods of treatment i |
| CN107952069A (zh) * | 2017-11-24 | 2018-04-24 | 长春百克生物科技股份公司 | 重组疫苗及其应用 |
| CN109985241B (zh) * | 2017-12-29 | 2024-10-18 | 广州威溶特医药科技有限公司 | Cdk抑制剂和溶瘤病毒在制备抗肿瘤药物的应用 |
| WO2020036635A2 (en) | 2018-03-19 | 2020-02-20 | Multivir Inc. | Methods and compositions comprising tumor suppressor gene therapy and cd122/cd132 agonists for the treatment of cancer |
| EP3773649A4 (en) * | 2018-03-28 | 2022-02-23 | EpicentRx, Inc. | PERSONALIZED CANCER VACCINE |
| CN112292449A (zh) | 2018-04-09 | 2021-01-29 | 萨克生物研究学院 | 具有增强的复制特性的溶瘤腺病毒组合物 |
| US20210340279A1 (en) | 2018-08-31 | 2021-11-04 | Yale University | Compositions and methods of using cell-penetrating antibodies in combination with immune checkpoint modulators |
| MX2021003013A (es) * | 2018-09-15 | 2021-08-11 | Memorial Sloan Kettering Cancer Center | Poxvirus recombinantes para inmunoterapia contra cáncer. |
| TWI852977B (zh) | 2019-01-10 | 2024-08-21 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
| EP3927833A4 (en) * | 2019-02-21 | 2022-11-30 | Unleash Immuno Oncolytics, Inc. | ONCOLYTIC ADENOVIRAL VECTOR AND METHODS OF USE |
| AU2020325825B2 (en) | 2019-08-05 | 2026-02-05 | Mesoblast International Sarl | Cellular compositions comprising viral vectors and methods of treatment |
| CR20220220A (es) | 2019-11-18 | 2022-09-20 | Janssen Biotech Inc | Vacunas basadas en calr y jak2 mutantes y sus usos |
| CN110859968A (zh) * | 2019-11-21 | 2020-03-06 | 四川安可康生物医药有限公司 | 激活对肿瘤的系统免疫反应的基因生物药物 |
| KR20220152250A (ko) * | 2020-03-06 | 2022-11-15 | 유니버시티 오브 피츠버그-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 | 암을 치료하기 위한 irf 모듈레이터를 발현하는 종양용해성 바이러스 |
| EP4164683A4 (en) * | 2020-06-10 | 2025-03-26 | Richard Lowenthal | GENETICALLY ENGINEERED ADENOVIRUS VECTORS AND USES THEREOF |
| EP4175664A2 (en) | 2020-07-06 | 2023-05-10 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
| CA3188492A1 (en) | 2020-08-10 | 2022-02-17 | Silviu Itescu | Cellular compositions and methods of treatment |
| JP7614980B2 (ja) | 2021-08-25 | 2025-01-16 | 三菱重工航空エンジン株式会社 | 燃焼器パネル、及びガスタービン用燃焼器 |
| EP4602078A2 (en) | 2022-10-11 | 2025-08-20 | Yale University | Compositions and methods of using cell-penetrating antibodies |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US5981725A (en) | 1989-09-08 | 1999-11-09 | The Johns Hopkins Univiersity | Structural alterations of the EGF receptor gene in human tumors |
| DE4228457A1 (de) | 1992-08-27 | 1994-04-28 | Beiersdorf Ag | Herstellung von heterodimerem PDGF-AB mit Hilfe eines bicistronischen Vektorsystems in Säugerzellen |
| US7252989B1 (en) | 1994-04-04 | 2007-08-07 | Board Of Regents, The University Of Texas System | Adenovirus supervector system |
| FR2722208B1 (fr) | 1994-07-05 | 1996-10-04 | Inst Nat Sante Rech Med | Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique |
| AU5551996A (en) | 1995-04-17 | 1996-11-07 | Board Of Regents, The University Of Texas System | An adenovirus helper-virus system |
| US5928906A (en) | 1996-05-09 | 1999-07-27 | Sequenom, Inc. | Process for direct sequencing during template amplification |
| US6682928B2 (en) * | 1997-12-02 | 2004-01-27 | Medarex, Inc. | Cells expressing anti-Fc receptor binding components |
| US6312700B1 (en) | 1998-02-24 | 2001-11-06 | Andrew D. Weinberg | Method for enhancing an antigen specific immune response with OX-40L |
| US7368527B2 (en) * | 1999-03-12 | 2008-05-06 | Human Genome Sciences, Inc. | HADDE71 polypeptides |
| US20030138405A1 (en) | 2001-04-17 | 2003-07-24 | Juan Fueyo | Conditionally replicative adenovirus to target the Rb and Rb-related pathways |
| CA2474777A1 (en) * | 2002-02-01 | 2003-08-07 | Transgene S.A. | Adenoviral vectors for modulating the cellular activities associated with pods |
| US20060147420A1 (en) * | 2004-03-10 | 2006-07-06 | Juan Fueyo | Oncolytic adenovirus armed with therapeutic genes |
| DE60317677T2 (de) | 2002-06-13 | 2008-10-30 | Crucell Holland B.V. | Ox40 (=cd134) rezeptor agonisten und therapeutische verwendung |
| US7291331B1 (en) | 2002-09-11 | 2007-11-06 | La Jolla Institute For Allergy And Immunology | Methods of treating OX40 medicated recall immune responses |
| KR20130065723A (ko) | 2003-06-27 | 2013-06-19 | 암젠 프레몬트 인코포레이티드 | 상피 성장 인자 수용체의 결실 돌연변이체 지향 항체 및 그 용도 |
| AU2006211960A1 (en) * | 2005-02-08 | 2006-08-17 | Board Of Regents, The University Of Texas System | Compositions and methods involving MDA-7 for the treatment of cancer |
| DK1877090T3 (da) | 2005-05-06 | 2014-04-14 | Providence Health System | Trimert ox40-immunoglobulin-fusionsprotein og fremgangsmåder til anvendelse heraf |
| DK2439273T3 (da) | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
| ES2304281B1 (es) * | 2006-02-01 | 2009-08-12 | Dnatrix Inc. | Adenovirus oncoliticos para el tratamiento del cancer. |
| KR101523391B1 (ko) | 2006-12-27 | 2015-05-27 | 에모리 유니버시티 | 감염 및 종양 치료를 위한 조성물 및 방법 |
| JP2012500855A (ja) | 2008-08-25 | 2012-01-12 | アンプリミューン、インコーポレーテッド | Ｐｄ−１アンタゴニストおよび感染性疾患を処置するための方法 |
| RU2573912C2 (ru) * | 2008-10-08 | 2016-01-27 | Интрексон Корпорейшн | Сконструированные клетки, экспрессирующие множественные иммуномодуляторы, и их применения |
| EP3255060A1 (en) | 2008-12-09 | 2017-12-13 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| CA2809089C (en) * | 2010-08-23 | 2018-12-18 | Board Of Regents, The University Of Texas System | Anti-ox40 antibodies and methods of using the same |
| US20130323205A1 (en) * | 2010-09-24 | 2013-12-05 | Oncos Therapeutics Oy | Oncolytic adenoviral vectors and methods and uses related thereto |
| EP3187603B1 (en) * | 2011-02-17 | 2024-06-26 | Arconic Technologies LLC | 2xxx series aluminum lithium alloys |
| ES2733211T3 (es) * | 2011-04-15 | 2019-11-28 | Genelux Corp | Cepas clonales de virus vaccinia atenuados y métodos de uso de las mismas |
| WO2013112942A1 (en) * | 2012-01-25 | 2013-08-01 | Dna Trix, Inc. | Biomarkers and combination therapies using oncolytic virus and immunomodulation |
| WO2013116778A2 (en) * | 2012-02-02 | 2013-08-08 | Board Of Regents | Immunogenic adenovirus |
-
2014
- 2014-11-21 CN CN201480073813.1A patent/CN106029889A/zh active Pending
- 2014-11-21 US US15/038,446 patent/US20160289645A1/en not_active Abandoned
- 2014-11-21 JP JP2016533143A patent/JP2016540505A/ja not_active Withdrawn
- 2014-11-21 SG SG10201907841U patent/SG10201907841UA/en unknown
- 2014-11-21 WO PCT/US2014/066920 patent/WO2015077624A1/en not_active Ceased
- 2014-11-21 EP EP19203386.8A patent/EP3653714A1/en not_active Withdrawn
- 2014-11-21 CA CA2931322A patent/CA2931322A1/en not_active Abandoned
- 2014-11-21 KR KR1020167016399A patent/KR20160137946A/ko not_active Ceased
- 2014-11-21 AU AU2014352749A patent/AU2014352749A1/en not_active Abandoned
- 2014-11-21 CN CN202111419932.6A patent/CN114317461A/zh active Pending
- 2014-11-21 EP EP14864921.3A patent/EP3071697B1/en active Active
- 2014-11-21 ES ES14864921T patent/ES2765489T3/es active Active
- 2014-11-21 DK DK14864921.3T patent/DK3071697T3/da active
-
2018
- 2018-06-27 US US16/020,738 patent/US20190093085A1/en not_active Abandoned
-
2019
- 2019-12-27 JP JP2019238013A patent/JP2020048582A/ja active Pending
-
2021
- 2021-06-11 US US17/304,006 patent/US20210301264A1/en not_active Abandoned
- 2021-06-11 JP JP2021097883A patent/JP2021137029A/ja active Pending
-
2024
- 2024-10-10 US US18/912,157 patent/US20250171745A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016540505A5 (enExample) | ||
| ES2765489T3 (es) | Adenovirus que expresa agonista(s) del receptor estimulante de células inmunitarias | |
| JP7480126B2 (ja) | がん免疫療法のための、組換えポックスウイルス | |
| ES2971065T3 (es) | Terapia de combinación de virus vaccinia oncolítica y un inhibidor de punto de control | |
| Lemay et al. | Harnessing oncolytic virus-mediated antitumor immunity in an infected cell vaccine | |
| JP2015506704A5 (enExample) | ||
| CN107847534B (zh) | Mva或mvaδe3l作为抗实体瘤的免疫治疗剂的应用 | |
| Koske et al. | Oncolytic virotherapy enhances the efficacy of a cancer vaccine by modulating the tumor microenvironment | |
| AU2017207532A1 (en) | Oncolytic virus and checkpoint inhibitor combination therapy | |
| EP3400293A1 (en) | Modified oncolytic virus | |
| CN117731763A (zh) | 过继细胞转移与溶瘤病毒组合疗法 | |
| BR112021001117A2 (pt) | células cancerígenas modificadas, composição farmacêutica, linha celular, métodos para fazer células cancerígenas modificadas e para estimular uma resposta imune, vetor de expressão isolado ou combinação de vetores de expressão isolados, e, uma ou mais células cancerígenas modificadas | |
| EP3829627A1 (en) | Viral vectors encoding cancer/testis antigens for use in a method of prevention or treatment of cancer | |
| Pol et al. | Oncolytic viruses: a step into cancer immunotherapy | |
| US12611444B2 (en) | IL-36 cytokine expressing oncolytic viruses for treating cancer | |
| US20240325473A1 (en) | Cancer Treatments | |
| CA3060516C (en) | Oncolytic vaccinia virus and checkpoint inhibitor combination therapy | |
| Olsen et al. | Neuro-Oncology Advances | |
| Witt | Cripto-1: potential target for cancer immunotherapy?! | |
| HK40097178A (en) | Oncolytic vaccinia virus and checkpoint inhibitor combination therapy | |
| HK40030022A (en) | Adenovirus expressing immune cell stimulatory receptor agonist(s) | |
| Rajani et al. | Viral platforms for expression of tumor antigens in cancer immunotherapy | |
| HK1230236A1 (en) | Adenovirus expressing immune cell stimulatory receptor agonist(s) | |
| Lohr et al. | Experimental treatment of pancreatic cancer | |
| HK40025045A (en) | Oncolytic vaccinia virus and checkpoint inhibitor combination therapy |